NASDAQ:IMTX Immatics Q3 2026 Earnings Results & Report $6.33 -0.10 (-1.59%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Immatics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.57 versus the -$0.49 consensus estimate, while revenue of $7.84 million fell short of the $12.18 million estimate by $4.34 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market Opens Immatics EPS ResultsActual EPS-$0.57Consensus EPS -$0.49Beat/MissMissed by -$0.08One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersImmatics Revenue ResultsActual Revenue$7.84 millionExpected Revenue$12.18 millionBeat/MissMissed by -$4.34 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Immatics Q3 2026 Earnings FAQ Did Immatics beat earnings estimates for Q3 2026? Immatics (NASDAQ:IMTX) reported earnings of -$0.57 per share for Q3 2026, missing the consensus estimate of -$0.49. The report was announced on Tuesday, November 10, 2026. What was Immatics' revenue for Q3 2026? Immatics reported revenue of $7.84 million for Q3 2026, against a consensus estimate of $12.18 million. Immatics Earnings HeadlinesImmatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 202652 minutes ago | marketscreener.comMImmatics (IMTX) Reports Q3 Loss, Lags Revenue EstimatesNovember 10 at 9:11 AM | finance.yahoo.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 10 at 1:00 AM | American Alternative (Ad)Immatics Reports Third-Quarter 2026 Results and Business UpdateNovember 10 at 7:31 AM | tipranks.comImmatics Announces Third Quarter 2026 Financial Results and Business UpdateNovember 10 at 7:00 AM | globenewswire.comImmatics N.V. (NASDAQ:IMTX) Stock Rated "Moderate Buy" by Sell-Side BrokeragesNovember 9 at 3:17 AM | americanbankingnews.comSee More Immatics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immatics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immatics and other key companies, straight to your email. Email Address About ImmaticsImmatics (NASDAQ:IMTX) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells. Immatics’ research focuses on targets derived from proteins inside tumor cells that can be presented on the cell surface. The company has operations in Europe and the United States, including locations in Germany and Houston, Texas. Immatics is a research and development company, with its work centered on advancing its oncology therapies through clinical development.View Immatics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
